Serglycin is the major proteoglycan in most hematopoietic cells, including monocytes and macrophages. The monoblastic cell line U937-1 was used to study the expression of serglycin during proliferation and differentiation. In unstimulated proliferating U937-1 cells serglycin mRNA is nonconstitutively expressed. The level of serglycin mRNA was found to correlate with the synthesis of chondroitin sulfate proteoglycan (CSPG). The U937-1 cells were induced to differentiate into different types of macrophage-like cells by exposing the cells to PMA, RA, or VitD3. These inducers of differentiation affected the expression of serglycin mRNA in three different ways. The initial upregulation seen in the normally proliferating cells was not observed in PMA treated cells. In contrast, RA increased the initial upregulation, giving a reproducible six times increase in serglycin mRNA level from 4 to 24 h of incubation, compared to a four times increase in the control cells. VitD3 had no effect on the expression of serglycin mRNA. The incorporation of ( 35 S)sulfate into CSPG decreased approximately 50% in all three differentiated cell types. Further, the ( 35 S)CSPGs expressed were of larger size in PMA treated cells than controls, but smaller after RA treatment. This was due to the expression of CSPGs, with CSchains of 25 and 5 kDa in PMA and RA treated cells, respectively, compared to 11 kDa in the controls. VitD3 had no significant effect on the size of CSPG produced. PMA treated cells secreted 75% of the ( 35 S)PGs expressed, but the major portion was retained in cells treated with VitD3 or RA. The differences seen in serglycin mRNA levels, the macromolecular properties of serglycin and in the PG secretion patterns, suggest that serglycin may have different functions in different types of macrophages.
Introduction
Macrophages are found in all organs of the body, in body cavities and their linings and in the skin. The cells constitute an important part of the defense system against microorganisms and transformed cells, but are also important as antigen presenters and secretory cells (Nathan, 1987; Öberg and Nilsson, 1996) . The functional abilities of tissue macrophages will, however, vary to a considerable extent, depending on the tissue of residence. All tissue macrophages are derived from blood monocytes, which in turn are again recruited from stem cells committed along the monocyte-macrophage lineage. The differentiation of cells in this lineage is initiated in the bone marrow (VanFurth, 1988) , and after residing in the circulation for 1-3 days the cells migrate into the tissues and give rise to tissue macrophages (Naito, 1993) . In the different tissues the final stages in macrophage differentiation will take place, resulting in the appearance of such cells as Kupffer cells, microglial cells, osteoclasts, peritoneal macrophages, etc. (VanFurth, 1988) . During inflammatory conditions several cytokines, chemokines, and indeed, other cell types, will modulate the functional capabilities of both monocytes and tissue macrophages, and in many cases promote increased recruitment of precursor cells from the bone marrow (Johnston, 1988) .
Cells in the monocyte-macrophage lineage secrete a wide range of cytokines, complement components, enzymes, chemokines (Öberg and Nilsson, 1996) , and also proteoglycans (PG). It has been established that serglycin is the major secretory PG of human monocytes (Kolset and Kjellén, 1986; Uhlin-Hansen et al., 1993) . Originally, serglycin was isolated from L2 rat yolk sac tumor cells (Oldberg et al., 1981) , and later cloned and sequenced (Bourdon et al., 1985) , and named serglycin (Ruoslahti, 1988) . Later work showed that serglycin is expressed in all hematopoietic cells analyzed (Tantravahi et al., 1986; Avraham et al., 1988; Périn et al., 1988; Giorda et al., 1990; Stellrecht et al., 1991; Uhlin-Hansen et al., 1993) . In human cells the core protein contains an 18 amino acid region with serine-glycine dipeptide repeats, which represent the glycosaminoglycan (GAG) attachment region of serglycin (Nicodemus et al., 1990) . In most blood cells chondroitin sulfate (CS) is found on this core protein, with the exception of connective tissue mast cells where heparin chains are attached to serglycin (Kolset and Gallagher, 1990) . Human serglycin may carry up to eight GAG chains in this short serine-glycine repeat region. The protein-core has been shown to be highly processed after secretion (Nicodemus et al., 1990; Uhlin-Hansen et al., 1993) . However, the remaining protein-core with attached GAG chains has been shown to be protease-resistant (Stevens et al., 1985) .
Serglycin represent an important constituent of the storage and secretory granules in mast cells (Matsumoto et al., 1995) , neutrophil and basophil granulocytes (Gullberg et al., 1997) , platelets (Périn et al., 1988) , and cytotoxic T cells (Masson et al., 1990) . Serglycin has also been found in nongranula producing cells such as lymphocytes and monocytes (Kolset and Gallagher, 1990 ) and shown to bind both chemokines and enzymes secreted from monocytes (Kolset et al., 1996) . In addition, serglycin has been shown to be a ligand for CD44 and proposed to be involved in cell-cell interactions (Toyama-Sorimachi et al., 1995) .
In addition to the major PG serglycin, monocytes and macrophages have been shown to express several other proteoglycans. Syndecan-1 and syndecan-4 expression have been detected in murine monocytes and macrophages and in different murine macrophage-like cell lines, Syndecan-4 expression being the most abundant (Yeaman and Rapraeger, 1993a,b) . Recently it has also been demonstrated by reverse transcriptase PCR technique that normal human monocytes express syndecan-2, syndecan-4, and glypican mRNA (Uhlin-Hansen et al., unpublished observations) . The function of these proteoglycans in monocytes and macrophages have not been defined.
The U937 monoblastic cell line was established from a histocytic lymphoma in 1976 (Sundström and Nilsson, 1976) and has since been widely used as an in vitro model for monocytic differentiation. To provide more information on the relationship between serglycin expression and differentiation of cells in the monocytic lineage, the subclone U937-1 (Åsjø et al., 1987) was induced to differentiate towards macrophage-like cells. This can be accomplished by exposing the cells to phorbol-12-myristate-13-acetate (PMA), retinoic acid (RA) or 1α,25-dihydroxycholecalciferol (VitD3), resulting in the generation of different types of macrophage-like cells (Öberg et al., 1993a) . Öberg et al. (1993b) suggested different functions for the different macrophages generated to be secretion, antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, respectively, a phenotypical heterogeneity relevant to different types of normal macrophages.
Results presented here show that the expression of serglycin mRNA differ between the different types of macrophage-like cells generated, and that it shows a particular pattern of expression during proliferation. Furthermore, the macromolecular properties of the CSPG and the pattern of secretion also varies between the differentiated cell types, suggesting that serglycin may have different functions in different types of macrophages.
Results

Serglycin and proliferation
The U937-1 cells were seeded in RPMI 1640 supplemented with 10% FCS and antibiotics, at a density of 0.3 × 10 6 /ml and cultured for 3 or 4 days. After 3 days the cell density had reached ∼1.3 ×10 6 /ml (insert in Figure 1B ). In the same time period the expression of serglycin mRNA relative to the level of the constitutively expressed β-actin mRNA, was measured ( Figure  1A ,B). A nonconstitutive expression of serglycin mRNA was observed. The level increased four times from 4 to 24 h of incubation. This initial upregulation was followed by a decrease the rest of the cultivation period.
To relate the level of serglycin mRNA to the synthesis of the actual proteoglycan (PG), the cells were labeled with ( 35 S)sulfate for 2 h prior to harvesting at 4, 24, 48, and 72 h of incubation. The ( 35 S)sulfate incorporation into macromolecules (chondroitin sulfate PG; see below) followed the same pattern as the level of serglycin mRNA. After 24 h the synthesis of ( 35 S)macromolecules (cell and medium total) was four times higher compared to the synthesis at 4 h of incubation. After 72 h the synthesis of ( 35 S)macromolecules was almost equal to that observed after 4 h ( Figure 1C ).
The significance of several factors for the observed nonconstitutive regulation of serglycin mRNA in normal proliferating U937-1 cells was investigated. The typical mRNA profile could be observed both in the absence and presence of serum in the culture medium, indicating that the regulation was independent of factors in serum. However, the initial upregulation was dependent of de novo protein synthesis as cycloheximide totally inhibited the upregulation of serglycin mRNA. Differences in starting cell density did not have any impact, as the same increase in the expression level could be observed at starting densities 0.3, 0.6, and 0.9 × 10 6 cells/ml. However, when U937-1 cells were incubated at a starting density of 0.3 × 10 6 /ml with increasing concentrations of conditioned medium (harvested from cells incubated for 3 days) a somewhat different pattern of expression could be observed. The level of serglycin mRNA after 24 h was 20% lower with 50% conditioned medium and 50% lower with 100% conditioned medium. In addition, the downregulation in serglycin mRNA expression observed after 24 h of incubation was prevented by daily media exchange. This could be due to the expression and secretion of a factor(s) that downregulate the expression of serglycin. This activity is not serglycin itself, as additions of purified serglycin ranging from 1 to 100 µg/ml had no effect on the serglycin mRNA profile observed.
Differentiation of U937-1 cells
With the aim to correlate serglycin expression to changes in cellular phenotypes, various inducers of differentiation were used. U937-1 cells were exposed to 0.16 µM phorbol 12-myristate 13-acetate (PMA), 1 µM retinoic acid (RA), and 0.1 µM 1α,25-dihydrocholecalciferol (VitD3). The proliferation of the cells was inhibited to different extents depending on the inducer used. After 3 days of incubation with VitD3, RA, or PMA, the number of cells was 71%, 37%, or 31% of the control. Furthermore, the cells adhered to the plastic surface in the presence of PMA, but remained nonadherent after exposure to RA and VitD3. To further investigate the differentiation of the cells, the mRNA levels for the cell surface antigens CD14 and CD23 was measured. CD14 is the receptor for complexes of LPS and LPS-binding protein (Wright et al., 1990) , whereas CD23 is an IgE low affinity receptor (Conrad, 1990) . Expression of CD14 mRNA could be detected in cells exposed to VitD3 for 24 h, but not in cells exposed to either RA or PMA, even after 72 h of incubation (results not shown). In contrast, the basal expression level of mRNA for CD23 was only upregulated in cells exposed to PMA and RA. PMA was a more potent inducer than RA, since the upregulation of CD23 mRNA could be observed after 24 h with PMA and 48 h with RA (results not shown). These findings are in agreement with previous results demonstrating the appearance of macrophage-like cells with different phenotypic markers after exposing U937-1 cells to PMA, RA or VitD3 (Öberg et al., 1993a) .
Serglycin mRNA and differentiation
To determine the effects of PMA, RA and VitD3 on proteoglycan expression, mRNA was isolated from U937-1 cells and the levels of serglycin mRNA were determined at different time points (Figure 2 ). The serglycin mRNA expression profile in VitD3 treated cells was the same as in control cells, increasing approximately 4 times from 4 to 24 h of incubation, and decreasing the rest of the cultivation period. PMA inhibited the initial upregulation observed in control cells. Furthermore, after 72 h the serglycin mRNA expression was lower than at the start of PMA treatment. Strikingly, RA stimulated the expression of serglycin mRNA approximately 6 times during the first 24 h, giving nearly a 150% higher level of expression than in control cells. The decrease in mRNA expression the next 48 h followed the same pattern as in control cells.
Expression of ( 35 S)CSPG
To determine the type of PGs expressed, U937-1 cells were cultured for 22 h with or without differentiation inducers and labeled with ( 35 S)sulfate for 2 h. ( 35 S)-Labeled macromolecules were treated with cABC and the products analyzed by Superose Fig. 2 . The effect of differentiation on serglycin mRNA expression. U937-1 control cells and cells exposed to 0.16 µM PMA, 1 µM RA, or 0.1 µM VitD3 were incubated for 3 days. At the indicated time points mRNA was isolated and subjected to Northern blot analyses. The membrane were sequentially hybridized with ( 32 P)-labeled serglycin cDNA and β-actin cDNA. The relative levels of serglycin mRNA in each sample are presented (as mean of duplicates). The experiment was performed three times with similar results. 6 gel chromatography. In material from all the cell cultures (both medium and cell fractions), and irrespective of differentiation inducer added, only depolymerized material could be detected after cABC treatment (results not shown). Accordingly, U937-1 cells expressed only ( 35 S)CSPG in both the undifferentiated and differentiated stages. The ( 35 S)-labeled macromolecules were analyzed by SDS-PAGE and only one band appeared both in the control and in the differentiated cells, indicating that serglycin is the predominant CSPG produced (results not shown).
To study further the effects of differentiation on the macromolecular properties of CSPG, untreated, PMA, RA and VitD3 stimulated cells were incubated for 24 h and labeled with ( 35 S)sulfate for 2 h. Cell and medium fractions were harvested, and the level of ( 35 S)CSPG expressed determined by Sephadex G-50 gel chromatography. The incorporation of ( 35 S)sulfate into CSPGs was two times higher (cell and medium total) in control cells compared to cells differentiated with PMA, RA, and VitD3 (Figure 3) . The lower level of ( 35 S)CSPG synthesis by RA treated cells is contrasted by the higher level of serglycin mRNA when compared to control cells, as shown in Figure 3 and 2, respectively. Furthermore, only in PMA treated cells was a decrease in serglycin mRNA expression found to correlate to a corresponding decrease in ( 35 S)CSPG synthesis. There is, accordingly, a striking difference between the level of serglycin mRNA and ( 35 S)CSPG synthesis in cells differentiated with RA and PMA. In addition, the serglycin mRNA levels in VitD3 treated cells were similar to those in control cells, whereas the ( 35 S)CSPG level after 24 h is ∼50% of control. These data indicate that there is a decrease in the capacity for GAG synthesis in differentiated cells, irrespective of the level of available protein template (see also section below on glycosaminoglycans).
In control, RA and VitD3 treated cells the cell fraction contained the major part (64-68%) of the ( 35 S)CSPG expressed during the 2 h labeling period. In contrast, the major part (∼75%) of the ( 35 S)CSPG expressed was recovered from the medium of PMA treated cells (Figure 3 ). This striking effect of PMA on CSPG secretion has been observed previously in U937-4 cells (Uhlin-Hansen et al., 1993) . One possible explanation for this effect could be that secretion of CSPG from PMA treated U937-1 cells is linked to the plastic adherence induced. To analyze this further, tissue culture flasks were coated with a thin layer of agarose A to prevent the plastic adherence of cells exposed to PMA. However, the lack of cell adhesion had no effect on the secretion pattern, which was identical to what is shown in Figure  3 . Consequently, PMA stimulation, with or without adherence to the tissue culture plastic, promoted secretion of ( 35 S)CSPG. When plastic adherence was inhibited with Agarose A, the PMA-treated cells created cell-cell aggregates, and this could in itself have an effect on the secretion.
Glycosaminoglycans
The level of mRNA expression observed in differentiated U937-1 cells was not reflected in the level of ( 35 S)sulfate incorporation into CSPG. To analyze this apparent discrepancy in further detail the ( 35 S)CSPGs were analyzed by Superose 6 gel filtration (Figure 4) . Material from medium fractions of control and VitD3 treated cells eluted with identical peak k av -values of 0.27. The ( 35 S)CSPGs from PMA-treated cells were, however, significantly larger in molecular size than the two former, displaying a peak k av -value of 0.15. In contrast, ( 35 S)CSPGs from the RA treated cells were significantly smaller in molecular size, eluting with a peak k av -value of 0.42. Similar results were obtained with the respective cell fractions (results not shown).
Chromatography of corresponding ( 35 S)-labeled material after alkali treatment revealed a shift in the elution patterns for all four fractions analyzed, demonstrating that chondroitin sulfate in the respective medium fractions were not free GAG chains, but part of PG molecules. The larger molecular mass of ( 35 S)CSPGs secreted by PMA treated cells was due to the larger size of the attached ( 35 S)CS chains, eluting with peak k av -values of 0.50, compared to the peak k av -value 0.65 for CS chains from control and 0.62 for VitD3 treated cells ( Figure 5 ). In contrast, the smaller size of the ( 35 S)CSPG expressed by RA treated U937-1 cells was due to the synthesis of smaller GAG chains with a k av -value of 0.73. The modulation of CS chain length observed after 24 h of incubation with RA or PMA, was not observed after only 4 h incubation, where the CS chains were shown to be of similar size.
The approximate molecular masses of the GAG chains liberated from the respective medium ( 35 S)CSPGs were determined on the basis of the k av-values of the peak elution fractions compared to those of chondroitin sulfate standards (Table I) . The peak molecular mass of the ( 35 S)CS chains in the control was ∼11 kDa, and 13 kDa in PGs from VitD3-treated cells. In PMA treated cells the GAG chains had an approximate molecular mass of 25 kDa, whereas the chains of( 35 S)CSPGs synthesized by RA treated cells were ∼5 kDa. 
Disaccharides
The differences observed in ( 35 S)sulfate incorporation could also be due to changes in the degree of sulfation of ( 35 S)CSPGs expressed. To address this problem disaccharides obtained after cABC treatment of medium and cell material from control, PMA, RA, and VitD3 treated cells were analyzed by HPLC. Monosulfated disaccharides of the ∆Di-4S type were found to be the predominant disaccharide in all fractions analyzed (not shown). Differentiation did not, accordingly, have any effect on the sulfation pattern of the CSPGs expressed. Changes in sulfation therefore cannot explain the difference in ( 35 S)sulfate incorporation (Figure 3 ) between control and inducer treated cells. The differences in molecular mass of the CS chains are striking. On the basis of the ( 35 S)sulfate incorporation into GAGs and the molecular masses of the GAG chains it should be possible to make an approximate calculation of the relative number of PG molecules expressed. The pronase sensitivity of serglycin is not changed in any of the differentiated cells (results not shown). In addition, the observed shift in elution profile from intact CSPG (Figure 4 ) to released CS-chains ( Figure 5 ), indicates that the changed size of CSPG was due to synthesis of CS chains with different length. It seems, therefore, logical to assume that the same number of CS chains are attached per core protein. Considering the equal sulfation pattern as well, RA treated cells would express almost the same number of PG molecules as the control, whereas the corresponding numbers in PMA-and VitD3-treated cells would be 20% and 40% of the control, respectively.
Discussion
In unstimulated, normally proliferating U937-1 cells the serglycin mRNA is nonconstitutively expressed. The level of serglycin mRNA was found to correlate with the synthesis of CSPG. The regulation is assumed to take place at the level of transcription, since the serglycin mRNA is quite stable (t 1/2 > 6 h; M. A. Kulseth, unpublished observations). The observed initial upregulation is dependent on de novo protein synthesis and the downregulation seems to be caused by factors secreted by the cells. It is not known, if this particular regulation of serglycin expression is a general phenomenon in hematopoietic cells. However, our data show that it is important to measure the mRNA level for serglycin at different time points to make accurate comparisons between different proliferating hematopoietic cells and to measure the effects of stimulators and differentiation inducers.
The U937-1 cells were induced to differentiate into different types of macrophage-like cells by exposing the cells to PMA, RA, or VitD3. These inducers of differentiation affected the expression of serglycin mRNA in three different ways. The initial upregulation seen in the normally proliferating cells was not observed in the PMA treated cells. However, RA increased the initial upregulation, giving a reproducible six times increase in serglycin mRNA level from 4 to 24 h of incubation compared to a four times increase in control cells. Stellrecht et al. (1991 Stellrecht et al. ( , 1993 postulated that the onset of serglycin mRNA expression is an early event during hematopoiesis, and that an additional upregulation is only observed during granule formation. Furthermore, a decrease in serglycin mRNA expression has been observed when HL60 cells were differentiated towards non-granule-containing monocytes/macrophages with PMA or γ-IFN (Maillet et al., 1992; Stellrecht et al., 1993; Whyzmuzis et al., 1993) , supporting the notion of no increase in serglycin expression unless granule genesis occur. Our observations suggest that the serglycin expression may be up-or downregulated depending on which type of macrophages are generated during differentiation.
Despite the lack of correlation between the serglycin mRNA level and the total GAG-synthesis, an inverse correlation was found between the level of serglycin mRNA and the size of the GAG-chains produced. RA-treated U937-1 cells expressed a higher level of serglycin mRNA ,but produced CSPG with shorter CS (5 kDa) than the undifferentiated cells (11 kDa). In contrast, PMA treatment reduced the serglycin mRNA expression, but resulted in CSPG with longer CS chains (25 kDa). VitD3 had no significant effects neither on the serglycin mRNA nor the CSPG produced. Differentiation of U937-1 with three different agents, gave rise to three different macrophage-like cell types which produced serglycin with three significantly different sizes.
A change in the molecular properties of serglycin have also been observed during differentiation of normal human monocytes. In vitro differentiated human macrophages expressed oversulfated CS chains, which were not found in human monocytes (Kolset et al., 1983; Kolset, 1986) . In addition, CSPG from in vitro differentiated human macrophages contained longer CS chains (21-23 kDa) than those expressed by undifferentiated freshly isolated monocytes (14-17 kDa) (Kolset and Kjellén, 1986) . Macrophages isolated from peritoneal fluid produced CSPG with CS chains of ∼16 kDa. Upon stimulation with LPS the size decreased to 12 kDa (Uhlin-Hansen et al., 1993) . Hence, the variation in size of CSPG observed after differentiation of U937-1 could resemble changes seen during differentiation of human monocytes into different types of macrophages in vivo.
Changing either the size or the sulfate density of the GAG chains may be two ways to regulate the ability of serglycin to bind other ligands, such as enzymes and chemokines. Proteoglycans isolated from in vitro differentiated human macrophages (oversulfated and longer GAG chains) had a higher affinity for fibronectin than the normally sulfated species (Kolset and Kjellén, 1986) . Increased molecular mass of CS chains has also been observed in CSPG expressed by smooth muscle cells during proliferation. Such a change increased the affinity of CSPG for low density lipoprotein (Camejo et al., 1993) . Differentiation of the U937-1 cells represent an convenient system to produce and isolate serglycin with different sizes, which could be used in functional studies.
One striking feature of the PMA differentiated cells was the stimulation of serglycin secretion. PMA treated U937-1 cells have been classified as a secretory type of macrophage-like cells (Öberg et al., 1993b) . The ability to secrete serglycin should therefore be included as a property of such cells. Increased secretion of serglycin has also been observed after activation of human peritoneal macrophages (Uhlin-Hansen et al., 1993) . Serglycin has been demonstrated to be a ligand for CD44, a cell surface adhesion molecule involved in cell-cell and cell-matrix interactions (Toyama-Sorimachi et al., 1995) , and to bind chemokines (Kolset et al., 1996) , which might suggest functions for serglycin linked to inflammatory conditions.
Materials and methods
Cell cultures
The human monoblastic cell line U937 clone 1 (U937-1) was cultured in RPMI 1640 supplemented with 10% fetal calf serum (BioWhittaker, Walkersville, MD) and antibiotics, 100 IU/ml of penicillin, and 50 µg/ml of streptomycin).
Differentiation was induced by exposing U937-1 cells, at a density of 3 × 10 5 cells/ml, to 0.16 µM phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO), 0.1 µM 1α,25-dihydroxycholecalciferol (VitD3), or 1 µM retinoic acid (RA) (Sigma). Tissue culture flasks coated with a thin layer of 1% Agarose A (Pharmacia, Uppsala, Sweden) were used in one experiment to prevent adhesion of the PMA stimulated cells. To inhibit protein synthesis the cells were treated with 2 µg/ml of cycloheximide for up to 48 h. Cellular viability was determined by the trypan blue exclusion test.
Conditioned medium was harvested from U937-1 cells after they had reached a density of ∼1 × 10 6 cells per ml, and added back to new cultures with or without dilution with fresh medium. mRNA mRNA was isolated from U937-1 cells, as described by the manufacturer, using Dynabeads Oligo (dT) 25 (Dynal A.S., Oslo, Norway). The mRNA was eluted in 0.05M 3-(N-Morfolino)-propanesulfonic acid (pH 7.0) containing 1 mM EDTA, 5.6% formaldehyde, 40% formamide and loading buffer (2 mM Na-phosphate buffer, 1% Ficoll-400 and 0.025% bromophenol blue). Approximately 1 µg mRNA was separated on 1% agarose gels containing 6.7% formaldehyde. RNA was blotted onto nylon membranes (HybondN+, Amersham; Sambrook et al., 1989) and hybridization was carried out according to Church and Gilbert (1984) . For the detection of serglycin transcripts, the open-reading-frame of a serglycin cDNA clone (Uhlin-Hansen et al., 1993) , for CD14 a SstI-XhoI fragment of a CD14 cDNA clone (Goyert et al., 1988) and for CD23 a PstI-BamHI fragment of a FcεRII cDNA clone (Kikutani et al., 1986) were used. Membranes were rehybridized with a human β-actin cDNA probe (Clontech Laboratories, Palo Alto, CA). The expression levels of mRNA for serglycin and β-actin were determined in each sample. The results presented show the levels of serglycin relative to the respective β-actin expression levels.
( 35 S)-Labeling and isolation of ( 35 S)macromolecules
U937-1 cells cultured in the absence or presence of differentiation inducers were labeled with ( 35 S)sulfate (300 µCi/ml) for 2 h after 2, 22, 46, and 70 h of cultivation. At the end of the labeling period, the medium fractions were harvested and the cells were solubilized in 4 M guanidine-HCl with 2% Triton X-100. To remove unincorporated ( 35 S)sulfate, 1 ml of the material was applied to a 4 ml column of Sephadex G50 Fine in 0.05 M Tris/HCl, pH 8.0 and 0.15 M NaCl and eluted with dH 2 O; 100 µl aliquots were counted for radioactivity in a scintillation counter after the addition of scintillation fluid. The rest of the material was immediately frozen and stored until further analyses.
Alkali and enzyme treatment
U937-1 cells were cultured in the presence of ( 35 S)sulfate with or without differentiation inducers. Both medium and cell fractions were harvested, unincorporated ( 35 S)sulfate removed by Sephadex G-50 gel chromatography and samples subjected to alkali treatment (0.5 M NaOH over night at room temperature, followed by neutralization with 0.5 M HCl), which results in the liberation of free ( 35 S)-GAG chains. Finally, the samples were analyzed by Superose 6 gel chromatography.
Corresponding fractions were also subjected to enzymatic treatment with chondroitinase ABC (cABC, EC 4.2.2.4, Seikagaku Kogyo Co., Tokyo, Japan) which depolymerizes chondroitin sulfate and dermatan sulfate. Incubations with cABC were performed at 37_C over night with 0.01 U enzyme per sample in 0.05M Tris-HCl (pH 8.0) containing 0.05 M sodium acetate and 0.1% bovine serum albumin.
U937-1 cells were cultured in the presence of ( 35 S)sulfate with or without differentiation inducers for 24h and the proteoglycans were isolated according to Kolset and Kjellén (1986) . Samples (10,000c.p.m.) were treated with pronase according to Stevens et al. (1985) and analyzed on a precasted 4-20% SDS-PAGE gel. The ( 35 S)proteoglycans were visualized in a Phosphor Imager.
Gel chromatography
Medium and cell fractions were subjected to Superose 6 gel chromatography (2000-5000 c.p.m.) both prior to and after alkali treatment or cABC treatment. The columns were run in 0.05 M Tris-HCl (pH 8.0) with 0.15 M NaCl and 0.5% Triton X-100. Fractions of 1 ml were collected and the radioactivity counted in a scintillation counter. Markers for void (V o ) and total volume (V t ) were blue dextran and ( 35 S)-sulfate, respectively. Chondroitin sulfate standards were used to estimate the molecular mass of the ( 35 S)CS chains. These standards were isolated from different cell types and analyzed on Sepharose 6B. The molecular mass were calculated according to Wasteson (1971) .
Disaccharides obtained from cABC treatment were chromatographed on a Lichrocart-NH 2 column (Merck, Darmstadt, Germany) in 0.15 M Na 2 HPO 4 -buffer, pH 7.0, with a continuous Na 2 SO 4 gradient (0.01-0.25 M) and a flow rate of 0.8 ml/min, using a Spectra Physics HPLC pump system (Spectra Physics Inc., Mountain View, CA). Fractions were analyzed for radioactivity and UV absorbance (A 232 ). Standards used were ∆Di-4S (2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-4-O-sulfo-D-galactose) and ∆Di-diS E (2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-4,6-di-O-sulfo-D-galactose) from Seikagaku Kogyo Co.
